Regeneron Pharmaceuticals, Inc. (REGN) - Moat Analysis

Business Model

25%

3.1/5

3.09

Revenue is driven by two franchises in chronic therapeutic areas, providing above-average demand visibility from patient retention dynamics without formal contractual backlog. Geographic concentration in the US and meaningful product concentration in Dupixent and EYLEA HD constrain business model durability, though non-discretionary chronic disease demand and a growing pipeline provide structural support.

Sub-dimension

Summary

Score

Revenue Predictability30%

3.25

Forward visibility of revenue: backlog, contracts, retention

3.25

Summary

Dupixent and EYLEA are treatments for serious chronic conditions where patients rarely self-discontinue effective therapy, providing durable repeat utilization visibility without formal contractual backlog. Total revenues grew from $8.5B in FY2020 to $14.3B in FY2025, though the FY2021-2022 REGEN-COV antibody cycle introduced significant non-recurring volatility in the core trajectory.

3.25

Product Diversification10%

2.50

Diversification across product lines, segments, and customers

2.50

Summary

Dupixent global net product sales of $17.8B in FY2025 and EYLEA HD plus EYLEA combined US net product sales of $7.9B together represent the overwhelming majority of company economics. Libtayo, Praluent, and Kevzara add breadth but revenue concentration in two franchises is pronounced.

2.50

Geographic Diversification15%

2.25

Distribution across regions and home-market dependence

2.25

Summary

Dupixent US net product sales of $13.2B represent approximately 74% of the $17.8B in global Dupixent net product sales, and EYLEA HD US net product sales of $4.4B in FY2025 are almost entirely domestic, placing the United States as the source of roughly 75% of total company economics.

2.25

Scalability20%

3.25

Ability to grow revenue without proportional cost increases

3.25

Summary

The VelocImmune antibody platform and Regeneron Genetics Center create leverage across the pipeline from shared discovery infrastructure, enabling multiple approved products from a single R&D engine. Manufacturing is capital-intensive, with FY2026 capex guidance of $1.1-1.3B including a new $2B factory under construction, limiting near-term operating leverage.

3.25

Revenue Quality25%

3.50

Nature of the revenue: contractual vs transactional, defensive vs discretionary

3.50

Summary

Dupixent and EYLEA treat serious chronic conditions where patients rarely discontinue effective therapy voluntarily, creating high-quality repeat utilization dynamics. Revenue is transactional rather than contractually locked in, and formulary and reimbursement decisions by payers and PBMs introduce material variability not present in subscription-based businesses.

3.50

Competitive Advantages

40%

2.8/5

2.81

Regeneron's innovation platform, particularly the Regeneron Genetics Center with more than two million sequenced human genomes, provides an identifiable target-discovery advantage over most peers. The core franchises face meaningful competition, however: Roche's Vabysmo in ophthalmology and AbbVie's Rinvoq in inflammatory disease have taken market share, and biosimilar entry into EYLEA 2mg is already active.

Sub-dimension

Summary

Score

Pricing Power30%

3.00

The company's ability to raise prices without losing customers

3.00

Summary

3.00

Switching Costs20%

3.00

How costly it is for customers to switch to a competitor

3.00

Summary

3.00

Network Effects20%

1.50

Whether the product becomes more valuable as more users join

1.50

Summary

1.50

Brand Strength15%

3.00

Degree to which brand drives premium pricing and loyalty

3.00

Summary

3.00

Innovation Barrier15%

3.75

How difficult it is for competitors to replicate the core technology

3.75

Summary

3.75

Full analysis requires login